|
|
|
Insider
Information: |
Coles N Anthony |
Relationship: |
|
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
9 |
|
Direct
Shares |
1,005,229 |
|
Indirect Shares
|
124,745 |
|
|
Direct
Value |
$35,883,953 |
|
|
Indirect Value
|
$4,728,990 |
|
|
Total
Shares |
1,129,974 |
|
|
Total
Value |
$40,612,943 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
1
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
0.0%
|
-2.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Vertex Pharmaceuticals Inc |
VRTX |
SVP, Comm. Ops. |
2005-02-03 |
74,540 |
2005-02-03 |
2,076 |
Premium* |
|
NPS Pharmaceuticals Inc |
NPSP |
President, COO & Direc... |
2008-03-17 |
220,066 |
2007-01-31 |
0 |
Premium* |
|
Onyx Pharmaceuticals Inc |
ONXX |
Chairman & CEO, Director |
2013-10-01 |
0 |
2008-03-31 |
0 |
Premium* |
|
Laboratory Corp of America |
LH |
Director |
2013-02-15 |
2,584 |
2011-01-03 |
0 |
Premium* |
|
Crispr Therapeutics Ag |
CRSP |
Director |
2016-10-24 |
0 |
2016-10-24 |
70,000 |
Premium* |
|
McKesson Corp |
MCK |
Director |
2020-08-17 |
0 |
2018-07-25 |
0 |
Premium* |
|
Regeneron Pharmaceuticals Inc |
REGN |
Director |
2024-01-02 |
1,393 |
2019-01-02 |
0 |
Premium* |
|
Kineta Ord Shs |
KA |
Executive Chair, Direc... |
2021-02-01 |
691,008 |
2021-02-01 |
52,669 |
Premium* |
|
Cerevel Therapeutics Holdings, I... |
CERE |
|
2024-05-10 |
15,638 |
2022-12-09 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
115 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 5 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CERE |
Cerevel Therapeutics Hold... |
|
|
2024-05-10 |
4 |
AS |
$42.10 |
$2,105,125 |
D/D |
(50,000) |
15,638 |
0 |
% |
|
CERE |
Cerevel Therapeutics Hold... |
|
|
2024-01-02 |
4 |
AS |
$42.24 |
$2,111,815 |
D/D |
(50,000) |
2,704 |
0 |
% |
|
CERE |
Cerevel Therapeutics Hold... |
|
|
2024-04-01 |
4 |
AS |
$42.33 |
$2,116,640 |
D/D |
(50,000) |
15,638 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2022-09-06 |
4 |
OE |
$371.40 |
$2,234,428 |
D/D |
6,000 |
6,793 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2022-12-28 |
4 |
OE |
$374.12 |
$2,546,410 |
D/D |
5,758 |
6,851 |
0 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
Chairman & CEO |
|
2013-10-01 |
4 |
D |
$125.00 |
$3,204,000 |
D/D |
(25,632) |
105,566 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2021-08-18 |
4 |
AS |
$650.00 |
$3,315,000 |
D/D |
(5,100) |
902 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2022-09-06 |
4 |
AS |
$576.73 |
$3,487,657 |
D/D |
(6,000) |
1,093 |
0 |
% |
|
ONXX |
Onyx Pharmaceuticals Inc |
President & CEO |
|
2012-10-16 |
4 |
OE |
$29.03 |
$3,888,295 |
D/D |
125,599 |
233,942 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2022-12-28 |
4 |
AS |
$707.87 |
$4,111,822 |
D/D |
(5,758) |
1,093 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2021-09-15 |
4 |
OE |
$345.47 |
$4,372,807 |
D/D |
11,948 |
12,850 |
0 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
President & CEO |
|
2012-08-08 |
4 |
OE |
$29.03 |
$7,257,500 |
D/D |
250,000 |
379,033 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2021-09-15 |
4 |
AS |
$651.36 |
$7,873,484 |
D/D |
(11,948) |
902 |
0 |
% |
|
ONXX |
Onyx Pharmaceuticals Inc |
Chairman & CEO |
|
2013-10-01 |
4 |
D |
$125.00 |
$13,195,750 |
D/D |
(105,566) |
0 |
0 |
- |
|
ONXX |
Onyx Pharmaceuticals Inc |
President & CEO |
|
2012-08-08 |
4 |
S |
$72.18 |
$19,538,404 |
D/D |
(270,690) |
108,343 |
0 |
- |
|
115 Records found
|
|
Page 5 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|